The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor.
The authors have previously demonstrated a favorable effect of high-dose methylprednisolone (HDMP), which can induce differentiation and apoptosis of leukemic cells in children with acute myeloblastic leukemia (AML). Here, they evaluate the effect of short-course HDMP in 2 children with acute myeloblastic leukemia (AML-M2) presented with myeloid tumor (MT). Methylprednisolone (20 or 30 mg/kg/day) was given orally, in a single dose, without using other antileukemic agents. Rapid cytoreduction in MT, peripheral blood, and bone marrow blasts was observed in both children following short-course (4 or 7 days) HDMP treatment, possibly due to HDMP-induced differentiation and apoptosis of leukemic cells. The effects of HDMP should be explored in patients with other subtypes of AML who present with MT.
Hiçsönmez
Gönül
G
Department of Pediatric Hematology, Ihsan Dogramaci Children's Hospital, Hacettepe University, Ankara, Turkey. gsonmez@hacettepe.edu.tr
Cetin
Mualla
M
Aslan
Deniz
D
Ozyürek
Emel
E
D015703:Antigens, CD / Q000187:drug effects; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001856:Bone Marrow Examination; D002454:Cell Differentiation / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D023981:Sarcoma, Myeloid / Q000188:drug therapy; D016896:Treatment Outcome
D015703:Antigens, CD; D000970:Antineoplastic Agents; D008775:Methylprednisolone